Oxford Medical Simulation (OMS), a leading provider of immersive clinical training, has successfully secured $6.6 million in growth financing. The investment comes from Salica Investments, a UK-based firm supporting high-growth companies. This new capital is earmarked to accelerate OMS's expansion into the United States and advance its innovative product development.
Strategic Investment for US Expansion
The primary objective for this funding is to scale OMS's presence within American health systems and academic institutions. This strategic push recognizes the US as a critical market for advanced healthcare education and technology. The investment will enable the company to build a stronger foothold and better serve its growing base of US partners.
A substantial portion of the capital will fuel product innovation, particularly in AI-driven clinical scenarios and learning analytics. OMS plans to enhance its platform with sophisticated workflow tools for a more effective training experience. These advancements aim to provide deeper insights into learner performance and improve educational outcomes for healthcare professionals.
Revolutionizing Clinical Training with VR
Founded in 2017, Oxford Medical Simulation provides virtual reality solutions that allow clinicians to practice in realistic scenarios. Using VR headsets, learners engage in interactive situations and receive personalized feedback to hone their skills safely. This repeatable training model allows for mastery of complex procedures without any risk to patients.
The company's technology directly addresses ongoing staffing pressures and the critical need for consistent training standards in healthcare. By offering an immersive and scalable solution, OMS helps institutions improve clinical readiness and support workforce development. This approach ensures a new generation of learners is better prepared for the challenges of modern medical practice.
Leadership Perspectives on the Partnership
Michael Wallace, CEO of Oxford Medical Simulation, stated that the financing enables confident investment in the company's next phase. He emphasized that partners in US healthcare are focused on outcomes like safer practice and better-prepared staff. This growth capital will accelerate the company's ability to meet these critical priorities for its clients.
Representing the investor, Usman Ali of Salica Investments expressed strong support for the OMS mission. He highlighted the company's differentiated and proven platform, which addresses the vital need for safe clinical practice environments. Salica is delighted to back OMS as it continues to scale its impact across the healthcare and education sectors.
A Track Record of Growth and Support
This latest funding round builds on a history of strong investor confidence in Oxford Medical Simulation's vision. The company previously completed a $12.4 million Series A round led by Frog Capital in 2024. This followed an earlier €2.4 million funding injection in 2022, demonstrating a consistent trajectory of growth.
Salica Investments has an established reputation for backing promising, high-growth businesses primarily within the United Kingdom. The firm operates a diverse set of private market funds investing across various sectors and stages. Its support for OMS aligns with its strategy of empowering innovative companies poised for significant expansion and impact.
This £5 million investment marks a pivotal moment for Oxford Medical Simulation, reinforcing its leadership in the medical simulation market. The partnership with Salica Investments will fuel expansion and innovation, enhancing the quality of clinical training globally. Ultimately, this collaboration promises to advance healthcare education, leading to better-prepared clinicians and improved patient safety outcomes.